Skip to Main Content

File this under “Nice try, but …

An Ohio congresswoman unsuccessfully attempted to make it possible for the U.S. Department of Health and Human Services to conduct an end run around companies that price drugs —  developed with taxpayer dollars — higher than what is charged in seven other high-income countries.


Last week, Rep. Marcy Kaptur (D-Ohio) introduced an amendment to a House appropriations bill that would have authorized HHS to exercise rights in a federal law which, under certain circumstances, would permit a company — other than the licensed patent holder — to make a lower-cost version of a drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!